- Home
- KMI vs INM Comparison
KMI vs INM Comparison
Compare KMI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- INM
- Stock Information
- Founded
- KMI 1936
- INM 1981
- Country
- KMI United States
- INM Canada
- Employees
- KMI N/A
- INM N/A
- Industry
- KMI Natural Gas Distribution
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- INM Health Care
- Exchange
- KMI Nasdaq
- INM Nasdaq
- Market Cap
- KMI 63.2B
- INM 5.0M
- IPO Year
- KMI 2011
- INM N/A
- Fundamental
- Price
- KMI $27.64
- INM $2.06
- Analyst Decision
- KMI Buy
- INM
- Analyst Count
- KMI 13
- INM 0
- Target Price
- KMI $31.23
- INM N/A
- AVG Volume (30 Days)
- KMI 13.2M
- INM 111.0K
- Earning Date
- KMI 10-22-2025
- INM 11-13-2025
- Dividend Yield
- KMI 4.25%
- INM N/A
- EPS Growth
- KMI 11.35
- INM N/A
- EPS
- KMI 1.22
- INM N/A
- Revenue
- KMI $15,969,000,000.00
- INM $4,942,633.00
- Revenue This Year
- KMI $11.56
- INM N/A
- Revenue Next Year
- KMI $5.11
- INM N/A
- P/E Ratio
- KMI $22.61
- INM N/A
- Revenue Growth
- KMI 3.97
- INM 7.50
- 52 Week Low
- KMI $23.94
- INM $1.72
- 52 Week High
- KMI $31.48
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- KMI 51.13
- INM 42.44
- Support Level
- KMI $27.00
- INM $2.04
- Resistance Level
- KMI $27.87
- INM $2.26
- Average True Range (ATR)
- KMI 0.54
- INM 0.14
- MACD
- KMI -0.05
- INM -0.01
- Stochastic Oscillator
- KMI 36.99
- INM 12.42
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in the US, with an interest in or an operator on more than 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.